Skip to main content

Featured Article: Pyroptosis: a new paradigm of cell death for fighting against cancer

New Content ItemPyroptosis is an inflammatory cell death usually caused by microbial infection, accompanied by activation of inflammasomes and maturation of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Gasdermin family proteins are the executors of pyroptosis. Cytotoxic N-terminal of gasdermins generated from caspases or granzymes proteases mediated cleavage of gasdermin proteins oligomerizes and forms pore across cell membrane, leading to release of IL-1β, IL-18. Pyroptosis exerts tumor suppression function and evokes anti-tumor immune responses. Therapeutic regimens, including chemotherapy, radiotherapy, targeted therapy and immune therapy, induce pyroptosis in cancer, which potentiate local and systemic anti-tumor immunity. On the other hand, pyroptosis of normal cells attributes to side effects of anti-cancer therapies.

In this review, we focus on the regulatory mechanisms of pyroptosis and the tumor suppressive function of pyroptosis. We discuss the attribution of pyroptosis in reprogramming tumor microenvironments and restoration of anti-tumor immunity and its potential application in cancer immune therapy.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

  1. Authors: Sara F.F. Almeida, Liliana Santos, Gabriela Sampaio-Ribeiro, Hugo R.S. Ferreira, Nuno Lima, Rui Caetano, Mónica Abreu, Mónica Zuzarte, Ana Sofia Ribeiro, Artur Paiva, Tânia Martins-Marques, Paulo Teixeira, Rui Almeida, José Manuel Casanova, Henrique Girão, Antero J. Abrunhosa…

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Call for papers: Organoids as clinically relevant models to tailor precision medicine in cancer treatment

Organoid teaser image

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

Organoids as clinically relevant models to tailor precision medicine in cancer treatment.

The 2023 Special Issue will accept Research Articles and Reviews regarding the latest highlights on this topic. Submit here.

  • Submission opens: 1st January 2023
  • Submission deadline: 31st December 2023

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Call for papers: CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

The Special Issue will accept Research Articles and Review in this topic.  Submit here

  • Submission opens: 1st April 2023
  • Submission deadline: 31st March 2024

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    97 days submission to accept (Median)

    2022 Usage 
    2,694,347 downloads
    4,666 Altmetric mentions